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Nuclease resistanceShort interfering RNA (siRNA) has been proven to be an utilizable tool for post-transcriptional gene
silencing research. In this study, we designed and synthesized two glucosamine analogues and tried to
modify the siRNA using these two glucosamine analogues at the 30-overhang region of siRNAs to improve
the nuclease resistance and to overcome some other weak points. The siRNAs modiﬁed with glucosamine
analogues had almost no effect of the thermal stability and showed strong resistance to nuclease degra-
dation. Some of them kept the same gene silencing activity level as unmodiﬁed siRNA.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.RNA interference (RNAi) has been a vital area of post-transcrip-
tional gene silencing research because of its high efﬁciency and se-
quence speciﬁcity in plants1 and mammalian cells.2 Moreover, a
chemically synthesized short interfering RNA (siRNA) duplex was
reported to induce an RNAi effect.3 RNAi technology, as a break-
through of gene therapy, beneﬁts many incurable diseases;4–8
however, there are still a number of obstacles for in vivo experi-
ments and further clinical testing, such as low nuclease resistance,
poor membrane permeability, and off-target effects. In the wake of
the elucidation of the RNAi mechanism, chemical modiﬁcation9–12
of siRNA is considered a potential approach to overcome these siR-
NA-related problems.
Until now, many chemical modiﬁcations of siRNAs at the 30-
overhang region or 50-end have been designed and synthe-
sized,13–16 most of which showed better thermal stability, nuclease
resistance, and other biological properties than the natural mole-
cules. In our laboratory, aromatic compounds or abasic nucleosides
were introduced at the 30-overhang region in previous studies
(Fig. 1).14–16 However, none of these modiﬁcations were aimed at
improving their afﬁnity for the cell membrane or charge neutral-
ization. Therefore, we searched for a residue with high membraneafﬁnity and a positive charge that could be introduced into the 30-
overhang region of siRNA, which was expected to improve cell
membrane penetration, nuclease resistance, and other properties.
The amino sugar glucosamine, which is a structural element of
the polysaccharides chitosan and chitin, is considered to be a good
candidate. It is known that glucosamine shows high membrane
afﬁnity.17 As a positively charged molecule, it can also neutralize
the negatively charged phosphates of siRNA. Furthermore, since
chitosan exists widely in organisms, such as the exoskeleton of
crustaceans and other arthropods and the cell wall of fungi,18 glu-
cosamine shows low toxicity to the human body.
Synthesis of modiﬁed glucosamine monomer units. To introduce
glucosamine into the 30-end of both sense and antisense siRNA
strands, we prepared glucosamine monomer unit 12, with a 10-C2
linker and 60-controlled pore glass (CPG) resin, as the solid support
for the DNA/RNA synthesizer from the starting material glucosa-
mine hydrochloride 1 (Scheme 1). Since directly introducing a thio-
phenyl group into the 10-position of nonprotected glucosamine
would result in an a/bmixture, it was necessary to protect the ami-
no and hydroxyl groups using phthalic anhydride and acetic anhy-
dride, respectively, to generate fully protected 2 in yield of 68%.
Treatment of thiophenol in the presence of a Lewis acid (BF3OEt2)
produced only b type 3 in 93% yield. Because of the failure to re-
move the phthalyl group during the post-treatment step of oligo-
nucleotide (ON) synthesis, we changed the protecting group to a
triﬂuoroacetyl group, which could be removed easily by aqueous
ammonia. Deprotection of the acetyl and phthalyl groups of 3 fol-
lowed by silylation of 60-OH, triﬂuoroacetylation of 20-NH2, and
Figure 1. Structures of the modiﬁed siRNAs.
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83%, respectively. In the presence of triﬂuoromethanesulfonic acid,
treatment of 2-benzyloxyethanol, N-iodosuccinimide with
molecular sieves 4 Å gave 8 in 78% yield. To remove the end of
the 2C linker, Pd(OH)2/C-catalyzed hydrogenating debenzylation
and 4,40-dimethoxytritylation were carried out to produce 9 and
10 in respective yields of 89% and 98%. Next, compound 10 was
desilylated by treatment with tetrabutylammonium ﬂuoride to af-
ford 11 in yield of 68%. Subsequently, compound 11was succinated
to yield the corresponding succinate linked to the CPG resin to gen-
erate solid support 12 (19 lmol/g).
Furthermore, in order to examine the difference of glucosa-
mine-modiﬁed siRNAs with/without a base moiety, we also syn-
thesized another type of glucosamine monomer unit that
included thymine at the 60-position by an improved synthesis
route (Scheme 2). In the presence of BF3OMe2, the treatment of
2-benzyloxyethanol to 2 could directly introduce a C2 linker into
the 10-position of glucosamine to give 13 in 67% yield, therebyScheme 1. Synthesis route of 60-abasic glucosamine monomer unit. Reagents and condit
rt, 68%; (b) PhSH, BF3OEt2, CH2Cl2, rt, 93%; (c) ethylenediamine, MeCN, reﬂux, 60%; (d) TI
2-benzyloxyethanol, NIS, TfOH, CH2Cl2, MS4 Å, rt, 78%; (h) H2, Pd(OH)2/C, THF, rt, 89%; (
pyridine, rt; (ii) CPG, EDC, DMF, rt, 19 lmol/g.skipping the thiophenylation step. On account of the side reaction
of the later Mitsunobu reaction, we deprotected the acetyl groups
of 13 by treatment with MeONa in MeOH to give 14 in 88% yield.
N3-Benzoylthymine was introduced into the 60-position of 14 by
the Mitsunobu reaction to afford 15 in 84% yield. After removing
the phthalyl group of the 20-position and the benzoyl group of thy-
mine, the synthesis strategy was the same as Scheme 1 to generate
16–19 in 87, 90%, quant., and 79% yields, respectively. Subse-
quently, the CPG resin-linked solid support 20 (37 lmol/g) was
synthesized by the succination of 19.
Synthesis of glucosamine analogue-modiﬁed siRNAs.We chose the
Renilla luciferase gene as the target sequence. The basic siRNA se-
quences were as follows: Renilla sense, 50-CUUCUUCGUCGAGACC-
AUG-30; Renilla antisense 50-CAUGGUCUCGACGAAGAAG-30. By
using 12 and 20, ONs containing X or Y were synthesized using
an automatic DNA/RNA synthesizer (Fig. 2). Each of these siRNA se-
quences were speciﬁed by their 30-overhang region (0–2 molecules
of thymidine and glucosamine analogue X or Y), and ﬂuorescent
amidites were also introduced at the 50-end of ONs 42–44 for fur-
ther assay tests.
The synthesized ONs were post-treated with the conventional
process11 and analyzed using matrix-assisted laser desorption/ion-
ization time-of-ﬂight mass spectrometry. The observed molecular
weights of these ONs coincided with their calculated molecular
weight.19
Thermal stability. Themelting temperatures (Tm) of these siRNAs
were recorded using a UV–visible spectrophotometer in a buffer of
10 mM Na2HPO4/NaH2PO4 (pH 7.0) containing 100 mM NaCl.
Absorbance at 260 nm was measured as a function of temperature
from 20 to 95 C with a 0.5 C/min increase. The Tm values of these
siRNAs are shown in Table 1. Neither of these 30-end modiﬁed siR-
NAs showed a signiﬁcant decrease of Tm compared with the
unmodiﬁed molecule TT (Tm = 76.1 C). Thus, we found that intro-
duction of glucosamine analogues at the 30-end of the ONs hadions: (a) (i) MeONa, MeOH, rt; (ii) phthalic anhydride, MeOH, rt; (iii) Ac2O, pyridine,
PSCl, pyridine, rt, 86%; (e) (CF3CO)2O, pyridine, rt, 79%; (f) BzCl, pyridine, rt, 83%; (g)
i) DMTrCl, pyridine, rt, 98%; (j) TBAF, THF, rt, 68%; (k) (i) succinic anhydride, DMAP,
Scheme 2. Synthesis route of 60-basic glucosamine monomer unit. Reagents and conditions: (a) 2-benzyloxyethanol, BF3OMe2, MeCN, reﬂux, 67%; (b) MeONa, MeOH, rt, 88%;
(c) N3-benzoylthymine, PPh3, DEAD, THF, rt, 84%; (d) ethylenediamine, EtOH, reﬂux, 87%; (e) (CF3CO)2O, pyridine, rt, 90%; (f) H2, Pd(OH)2/C, THF, rt, quant; (g) DMTrCl,
pyridine, rt, 79%; (h) (i) succinic anhydride, DMAP, pyridine, rt; (ii) CPG, EDC, DMF, rt, 37 lmol/g.
Figure 2. Structures of the siRNAs in this study.
X. Luo et al. / Bioorg. Med. Chem. Lett. 23 (2013) 4157–4161 4159almost no effect on the thermal stability of the siRNA duplexes.
Moreover, the Tm values of the X- and Y-end siRNAs (22/23, 24/
25, and 26/27) were slightly different, which could indicate that
the nonthymine-containing glucosamine (X) siRNAs were more
thermally stable than the thymine-containing glucosamine (Y)
siRNAs.
Nuclease resistance. We tested the nuclease resistance of the 30-
end modiﬁed ONs 43 and 44 and the unmodiﬁed ON 42 against a
30-exonuclease, snake venom phosphodiesterase (SVPD). After
incubation in SVPD solution, degradation of the ONs was evaluated
using polyacrylamide gel electrophoresis analysis under denatur-
ing conditions (Fig. 3). The unmodiﬁed ON 42 was degraded bymore than 95% after 3 min, in contrast, the modiﬁed ONs 43 and
44 were degraded by less than 40% after 3 min and approximately
30% still remained after 5 min. Therefore, the introduction of glu-
cosamine analogues at the 30-end of siRNAs signiﬁcantly improved
their resistance against SVPD nuclease.
Gene silencing of Renilla luciferase. Furthermore, we examined
the gene silencing activity of each of these modiﬁed siRNAs using
a dual-luciferase assay in HeLa cells targeted to the Renilla lucifer-
ase gene.20 HeLa cells were co-transfected with the psiCHECK-2
vector containing Renilla luciferase and ﬁreﬂy luciferase and the
indicated amount of siRNA. The results were normalized by ﬁreﬂy
luciferase activity and the gene silencing efﬁcacy of each siRNA
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Figure 4. Dual-luciferase assay.
Table 1
Sequences of synthesized ONs used in this study
No. of siRNA No. of ON Sequence Tm (C)
siRNA 21 ON 28 50-CUUCUUCGUCGAGACCAUGtt-30 76.1
ON 29 50-CAUGGUCUCGACGAAGAAGtt-30 ––
siRNA 22 ON 30 50-CUUCUUCGUCGAGACCAUGX-30 75.4
ON 31 50-CAUGGUCUCGACGAAGAAGX-30 ––
siRNA 23 ON 32 50-CUUCUUCGUCGAGACCAUGY-30 75.2
ON 33 50-CAUGGUCUCGACGAAGAAGY-30 ––
siRNA 24 ON 34 50-CUUCUUCGUCGAGACCAUGtX-30 75.5
ON 35 50-CAUGGUCUCGACGAAGAAGtX-30 ––
siRNA 25 ON 36 50-CUUCUUCGUCGAGACCAUGtY-30 75.1
ON 37 50-CAUGGUCUCGACGAAGAAGtY-30 ––
siRNA 26 ON 38 50-CUUCUUCGUCGAGACCAUGttX-30 74.5
ON 39 50-CAUGGUCUCGACGAAGAAGttX-30 ––
siRNA 27 ON 40 50-CUUCUUCGUCGAGACCAUGttY-30 74.0
ON 41 50-CAUGGUCUCGACGAAGAAGttY-30 ––
–– ON 42 F-50-CAUGGUCUCGACGAAGAAGtt-30 ––
–– ON 43 F-50-CAUGGUCUCGACGAAGAAGtX-30 ––
–– ON 44 F-50-CAUGGUCUCGACGAAGAAGtY-30 ––
aUpper case letters indicate ribonucleosides and lower-case letters show 20-
deoxyribonucleosides.
bF denotes ﬂuorescein.
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Figure 3. Nuclease resistance of ONs 4244 against SVPD.
4160 X. Luo et al. / Bioorg. Med. Chem. Lett. 23 (2013) 4157–4161was assessed as a percentage of the control sample (Fig. 4). Renilla
luciferase was suppressed by each of these siRNAs in a dose-
dependent manner. Moreover, the Y-modiﬁed (thymine-contain-
ing) siRNAs showed better activity (siRNA 23 > siRNA 22, siRNA
25 > siRNA 24, siRNA 27 > siRNA 26) than the X-modiﬁed (non-thy-
mine-containing) siRNAs at 1 nM. We supposed that the thymine
glucosamine could be a better choice for the 30-overhang region
modiﬁcation of siRNAs.
In conclusion, we demonstrated a simple method for preparing
glucosamine monomer units (with/without a base moiety at the 60-position) that could be introduced to the 30-overhang region of siR-
NAs. Compared with unmodiﬁed siRNA, glucosamine modiﬁcation
of siRNAs did not affect their thermal stability. It was also found
that the X-modiﬁed siRNAs were more stable than the Y-modiﬁed
molecules. These modiﬁed siRNAs showed an obvious improve-
ment of resistance to nuclease degradation. All of these siRNAs
suppressed Renilla luciferase in a dose-dependent manner and
the Y-modiﬁed siRNAs showed better activity than the X-modiﬁed
siRNAs at 1 nM.
Besides ribose and aromatic series modiﬁcations at the 30-over-
hang region of siRNA, modiﬁcation with a glucosamine analogue
represents a new direction for siRNA chemical modiﬁcation re-
search. In this study, glucosamine monomer unit-modiﬁed siRNAs
showed some improvement of nuclease resistance. It is expected
that further study of glucosamine dimers or other base-containing
analogues will overcome more of the problems associated with
RNAi technology.
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